Literature DB >> 33596362

Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy.

Elise A Chong1, Marco Ruella1, Stephen J Schuster1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33596362     DOI： 10.1056/NEJMc2030164

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  40 in total

1.  Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy.

Authors:  Roni Shouval; Ana Alarcon Tomas; Joshua A Fein; Jessica R Flynn; Ettai Markovits; Shimrit Mayer; Aishat Olaide Afuye; Anna Alperovich; Theodora Anagnostou; Michal J Besser; Connie Lee Batlevi; Parastoo B Dahi; Sean M Devlin; Warren B Fingrut; Sergio A Giralt; Richard J Lin; Gal Markel; Gilles Salles; Craig S Sauter; Michael Scordo; Gunjan L Shah; Nishi Shah; Ruth Scherz-Shouval; Marcel van den Brink; Miguel-Angel Perales; Maria Lia Palomba
Journal:  J Clin Oncol       Date:  2021-12-03       Impact factor: 44.544

Review 2.  Hypogammaglobulinemia After Chimeric Antigen Receptor (CAR) T-Cell Therapy: Characteristics, Management, and Future Directions.

Authors:  Jeanette Wat; Sara Barmettler
Journal:  J Allergy Clin Immunol Pract       Date:  2021-10-28

Review 3.  Cellular kinetics: A clinical and computational review of CAR-T cell pharmacology.

Authors:  Timothy Qi; Kyle McGrath; Raghuveer Ranganathan; Gianpietro Dotti; Yanguang Cao
Journal:  Adv Drug Deliv Rev       Date:  2022-07-06       Impact factor: 17.873

4.  Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer.

Authors:  Yong Gu Lee; Puneeth Guruprasad; Guido Ghilardi; Raymone Pajarillo; Christopher Tor Sauter; Ruchi Patel; Hatcher J Ballard; Seok Jae Hong; Inkook Chun; Nicholas Yang; Kimberly V Amelsberg; Katherine D Cummins; Jakub Svoboda; Saar Gill; Elise A Chong; Khrystyna North; Sarah E Church; Joseph A Fraietta; Wan-Jung Chang; Simon F Lacey; Xueqing Maggie Lu; Yunlin Zhang; Kanupriya Whig; David C Schultz; Sara Cherry; James Gerson; Stephen J Schuster; Patrizia Porazzi; Marco Ruella
Journal:  Cancer Discov       Date:  2022-10-05       Impact factor: 38.272

Review 5.  A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains.

Authors:  Kathryn M Cappell; James N Kochenderfer
Journal:  Nat Rev Clin Oncol       Date:  2021-07-06       Impact factor: 66.675

Review 6.  The role of axicabtagene ciloleucel as a treatment option for patients with follicular/marginal zone lymphoma.

Authors:  Jose Sandoval-Sus; Julio C Chavez
Journal:  Ther Adv Hematol       Date:  2021-05-29

7.  Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission.

Authors:  Mazyar Shadman; Marcelo Pasquini; Kwang Woo Ahn; Yue Chen; Cameron J Turtle; Peiman Hematti; Jonathon B Cohen; Farhad Khimani; Siddhartha Ganguly; Reid W Merryman; Jean A Yared; Frederick L Locke; Nausheen Ahmed; Pashna N Munshi; Amer Beitinjaneh; Patrick M Reagan; Alex F Herrera; Craig S Sauter; Mohamed A Kharfan-Dabaja; Mehdi Hamadani
Journal:  Blood       Date:  2022-03-03       Impact factor: 22.113

8.  Willingness to Travel for Cellular Therapy: The Influence of Follow-Up Care Location, Oncologist Continuity, and Race.

Authors:  Zachary A K Frosch; Esin C Namoglu; Nandita Mitra; Daniel J Landsburg; Sunita D Nasta; Justin E Bekelman; Raghuram Iyengar; Carmen E Guerra; Marilyn M Schapira
Journal:  JCO Oncol Pract       Date:  2021-09-15

Review 9.  The Tumor Microenvironment in Follicular Lymphoma: Its Pro-Malignancy Role with Therapeutic Potential.

Authors:  Takashi Watanabe
Journal:  Int J Mol Sci       Date:  2021-05-19       Impact factor: 5.923

Review 10.  Myeloid-Derived Suppressor Cells: Implications in the Resistance of Malignant Tumors to T Cell-Based Immunotherapy.

Authors:  Houhui Shi; Kai Li; Yanghong Ni; Xiao Liang; Xia Zhao
Journal:  Front Cell Dev Biol       Date:  2021-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.